Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE HIVES versus PROMETHACON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE HIVES versus PROMETHACON.
CETIRIZINE HYDROCHLORIDE HIVES vs PROMETHACON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist of histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and gastrointestinal tract.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
10 mg orally once daily; maximum 10 mg per day.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 8–11 hours in healthy adults (mean ~8.3 h). In renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 20–30 hours, requiring dose adjustment.
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Approximately 70% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion, with about 10% excreted in feces. Biliary elimination is minimal.
Renal (80%) as inactive metabolites, 20% fecal via bile
Category A/B
Category C
Antihistamine
Antihistamine